AVXL
Anavex Life Sciences
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 275.07M; Volume: 387.77K; AvgVol 3m: 638.05K; Beta: 1.58;
Cost estimate:
P/E: –; EPS: -0.43; EPS growth quarter/prev quarter: 16.50%;
EPS growth this year: -39.20%; EPS growth past 5 years: 12.00%;
EPS ttm: -0.43;
P/S: ; P/B: 10.27; P/Cashflow: ; P/FCF: ;
Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -81.10%; ROE – return on equity: -101.10%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 4.17%; Insider Transactions:0.00%;
Institutional Ownership: 20.00%; Institutional Transactions: 2.26%;
Data update: 07/10/2020.